Literature DB >> 27578820

Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.

Kimberly Sciarretta1, John-Arne Røttingen2, Aleksandra Opalska3, Arjon J Van Hengel4, Joseph Larsen5.   

Abstract

The Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) in 2015 was tasked with exploring economic incentives for antibacterial drug development and providing recommendations for potential global implementation. Due to the continual decline of pharmaceutical companies investing in new antibiotic development and the rise in antimicrobial resistance, there is an urgent need to examine market mechanisms that are appropriate to encourage small, medium, and large companies to reinvest in this space. This review provides a summary of the various models that have been proposed and highlights positions posed by several policy documents, peer-reviewed publications, organization proposals, and government-sponsored reviews. The findings support a form of a de-linkage model and a combination of push and pull incentive mechanisms. This level of consensus could culminate in global coordination of incentives that strike a balance of rewarding innovation and ensuring appropriate antibiotic use. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Keywords:  TATFAR; antibiotic resistance; antimicrobials; economic incentives

Mesh:

Substances:

Year:  2016        PMID: 27578820     DOI: 10.1093/cid/ciw593

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Authors:  Henry F Chip Chambers; Heather R Cross; Scott R Evans; Barry N Kreiswirth; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

2.  Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.

Authors:  Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

3.  The Antibacterial, Antitumor Activities, and Bioactive Constituents' Identification of Alectra sessiliflora Bacterial Endophytes.

Authors:  Mehabo Penistacia Maela; Hendriëtte van der Walt; Mahloro Hope Serepa-Dlamini
Journal:  Front Microbiol       Date:  2022-07-05       Impact factor: 6.064

4.  An assessment of the future impact of alternative technologies on antibiotics markets.

Authors:  Ejike Nwokoro; Ross Leach; Christine Årdal; Enrico Baraldi; Kellie Ryan; Jens Plahte
Journal:  J Pharm Policy Pract       Date:  2016-10-26

5.  Revisiting aminocoumarins for the treatment of melioidosis.

Authors:  S J Willcocks; F Cia; A F Francisco; B W Wren
Journal:  Int J Antimicrob Agents       Date:  2020-04-30       Impact factor: 5.283

6.  Chitosan Films for Microfluidic Studies of Single Bacteria and Perspectives for Antibiotic Susceptibility Testing.

Authors:  Julie Tréguier; Loic Bugnicourt; Guillaume Gay; Mamoudou Diallo; Salim Timo Islam; Alexandre Toro; Laurent David; Olivier Théodoly; Guillaume Sudre; Tâm Mignot
Journal:  mBio       Date:  2019-08-20       Impact factor: 7.867

7.  Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data.

Authors:  Cornelius J Clancy; Brian A Potoski; Deanna Buehrle; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2019-07-28       Impact factor: 3.835

Review 8.  Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.

Authors:  Natalie K Boyd; Chengwen Teng; Christopher R Frei
Journal:  Front Cell Infect Microbiol       Date:  2021-05-17       Impact factor: 5.293

Review 9.  Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution?

Authors:  Matthew J Cheesman; Aishwarya Ilanko; Baxter Blonk; Ian E Cock
Journal:  Pharmacogn Rev       Date:  2017 Jul-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.